19 completed, 8 recruiting, 5 terminated, 2 suspended. 20 Phase 2, 17 Phase 1, 2 Phase 3, 1 Early Phase 1, 1 Phase 4.
Follow mogamulizumab: new trials by email Literature Review of mogamulizumab trials Research Report on mogamulizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of VG712 in Patients With Mycosis Fungoides VG712, Mogamulizumab - Mycosis Fungoides | Phase 2 | Not yet recruiting | Virogen Biotechnology Inc. | 386 | 2026-07-30 | 2026-04-14 |
| Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance Poteligeo 20mg - Mycosis Fungoides, Sezary Syndrome | Recruiting | Kyowa Kirin Co., Ltd. | 15 | 2025-05-02 | 2025-09-22 | |
| A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1 Mogamulizumab - T-Cell Leukemia/Lymphoma, Adult, T-cell Leukemia/Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 134 | 2024-11-15 | 2026-03-05 |
| Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma Mogamulizumab, DA-EPOCH Protocol, CHOEP protocol - T Cell Lymphoma, T-cell Lymphoma | Phase 2 | Recruiting | Yale University | 22 | 2024-10-09 | 2026-04-14 |
| Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT) Mogamulizumab-Kpkc, Phototherapy - Mycosis Fungoides | Early Phase 1 | Suspended | H. Lee Moffitt Cancer Center and Research Institute | 20 | 2024-01-18 | 2026-02-27 |
| Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas Pembrolizumab, Mogamulizumab - Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 23 | 2023-12-06 | 2026-05-05 |
| A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy Mogamulizumab - Cutaneous T-Cell Lymphoma | Phase 4 | Completed | Kyowa Kirin China Pharmaceutical Co., Ltd. | 23 | 2023-05-29 | 2026-09-09 |
| Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides Mogamulizumab, Brentuximab vedotin - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 1 | Suspended | University of Alabama at Birmingham | 10 | 2023-05-01 | 2026-06-15 |
| Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma Mogamulizumab, Total Skin Electron Beam Therapy (TSEB), Mogamulizumab (subsequent cycles post TSEB) - Stage IB-IIB Cutaneous T-Cell Lymphoma | Phase 2 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 43 | 2023-03-07 | 2024-04-05 |
| Real World Observational Study of Poteligeo in Adult Patients With MF and SS (PROSPER) Poteligeo - Mycosis Fungoides and Sézary Syndrome | Completed | Kyowa Kirin Pharmaceutical Development Ltd | 73 | 2022-11-09 | 2026-06-26 | |
| Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment - Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 34 | 2022-10-19 | 2026-09-02 |
| Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma Cyclophosphamide, Fludarabine, Mogamulizumab - Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Phase 1 | Recruiting | John Reneau | 12 | 2022-05-06 | 2026-02-10 |
| Mogamulizumab Q4week Dosing in Participants With R/R CTCL Mogamulizumab - Cutaneous T-Cell Lymphoma, Relapsed, Cutaneous T-Cell Lymphoma Refractory | Phase 2 | Unknown | Kyowa Kirin, Inc. | 34 | 2021-08-16 | 2024-04-25 |
| Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment - Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Emory University | 5 | 2021-04-21 | 2024-08-13 |
| Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment Biospecimen Collection, Computed Tomography, Magrolimab - Mycosis Fungoides, Recurrent Mycosis Fungoides | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 8 | 2021-04-06 | 2025-10-16 |
| Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome Mogamulizumab, LD TSEBT - Sezary Syndrome, Mycosis Fungoides | Phase 2 | Recruiting | Stanford University | 30 | 2020-03-30 | 2026-07-01 |
| Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome Recombinant human Interleukin-15 (rhIL-15), Mogamulizumab - Adult T-Cell Lymphoma/Leukemia, Sezary Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 6 | 2020-02-26 | 2023-01-04 |
| Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma Mogamulizumab, Pembrolizumab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 8 | 2018-10-24 | 2023-09-21 |
| A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM) KW-0761 0.3 mg/kg IV, Placebo (saline) - HTLV-1 Associated Myelopathy | Phase 3 | Terminated | Kyowa Kirin Co., Ltd. | 66 | 2017-05-22 | 2022-04-14 |
| KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors KHK2455, Mogamulizumab - Solid Tumor, Cancer | Phase 1 | Completed | Kyowa Kirin, Inc. | 36 | 2016-08-01 | 2024-04-25 |
Showing 20 of 38. Sign in to see all of them.
Lymphoma, T-Cell, Cutaneous (11) · Mycosis Fungoides (10) · Sezary Syndrome (8) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (5) · Leukemia-Lymphoma, Adult T-Cell (4) · Lymphoma, T-Cell, Peripheral (4) · Neoplasms (3) · Carcinoma (2) · Lymphoma, T-Cell (2) · Recurrence (2) · Asthma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Esophageal Neoplasms (1) · Glioblastoma (1)
Kyowa Kirin Co., Ltd. (9) · Kyowa Kirin, Inc. (8) · National Cancer Institute (NCI) (3) · Memorial Sloan Kettering Cancer Center (2) · Aichi Medical University (1) · Amgen (1) · City of Hope Medical Center (1) · Emory University (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · John Reneau (1) · Kyowa Kirin China Pharmaceutical Co., Ltd. (1) · Kyowa Kirin Pharmaceutical Development Ltd (1) · Osaka University (1) · Pfizer (1)
United States (26) · Japan (8) · France (6) · United Kingdom (6) · Italy (5) · Spain (5) · Denmark (3) · Netherlands (3) · Germany (2) · Australia (1) · Belgium (1) · Brazil (1) · China (1) · Greece (1) · Peru (1)
Michael Kurman, MD (2) · Christiane R Querfeld (1) · Dale R Shepard, MD, PhD (1) · Dmitri O. Grebennik, MD (1) · Erel Joffe (1) · Esra E Cohen, MD (1) · HaeMi Park (1) · Hisashi Wada, M.D., Ph.D (1) · Jan Nicolay (1) · Jedd Wolchok, MD, PhD (1) · John C Reneau, MD, PhD (1) · Lauren Shea, M.D. (1) · Lubomir Sokol, MD, PhD (1)
PMID 22312108, PMID 24616310, PMID 25605368, PMID 25733162, PMID 27418646, PMID 30100375, PMID 31801624, PMID 32586937, PMID 33883258, PMID 34907192, PMID 37729184, PMID 38430272, PMID 39315857, PMID 40180420, PMID 40536766, PMID 40546724, PMID 41595202
P30CA033572 (1), P30CA138292 (1), UM1CA186691 (1), UM1CA186717 (1)